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Abstract
Background: Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycaemia.
Increased oxidative stress and decreased antioxidant levels are the leading cause of diabetes and
diabetic complications. So it is felt that supplementation of antioxidants may be useful in controlling
the glucose levels and to postpone the occurrence of diabetic complications. The objective of our
study is to find the influence of antioxidant supplementation (L-ascorbic acid) on tolbutamide
activity in normal and diabetic rats.
Methods: L- ascorbic acid/tolbutamide/L-ascorbic acid + tolbutamide were administered orally to
3 different groups of albino rats of either sex in normal and diabetic condition. Blood samples were
collected from retro-orbital puncture at different time intervals and were analyzed for blood
glucose by GOD-POD method. Diabetes was induced by alloxan 100 mg/kg body weight
administered by I.P route.
Results:  L-ascorbic acid/ tolbutamide produced hypoglycaemic activity in a dose dependant
manner in normal and diabetic condition. In the presence of L-ascorbic acid, tolbuatmide produced
early onset of action and maintained for longer period compared to tolbutamide matching control.
Conclusion:  Supplementation of antioxidants like L-ascorbic acid was found to improve
tolbutamide response in normal and diabetic rats.
Background
Diabetes mellitus is a chronic metabolic disorder charac-
terized by hyperglycaemia. It requires life long treatment
with drugs coupled with diet control and exercise. It may
be due to decrease in the synthesis of insulin (Type-I dia-
betes) or due to decrease in the secretion of insulin from
β -cells of islets of Langerhans of pancreas (Type-II diabe-
tes). Insulin is the drug of choice in type – I diabetes and
sulfonylureas are the drugs of choice in type II. Among
sulfonylureas, tolbutamide is the drug of choice for geriat-
rics because of its short duration of action and lower inci-
dence of hypoglycaemia in early hours of night.
Diabetes is one of the stress related disorder. Diabetic sub-
jects are shown to have increased oxidative stress and
decreased antioxidant levels [1-3]. It was also shown that
tight control of blood glucose is possible with decrease in
oxidative stress [4]. Antioxidants are claimed to work as
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antistress agents by decreasing oxidative stress. L-ascorbic
acid used in therapy for disorders like scurvy produces
antioxidant activity. Earlier reports show that the relation-
ship between scurvy and diabetes mellitus indicates the
low levels of plasma ascorbic acid in diabetic rats com-
pared to control rats [5,6]. Hence the present study was
conducted to find the influence of L-ascorbic acid, a water
soluble antioxidant and a free radical scavenger on the
hypoglycaemic and antihyperglycaemic activities of tolb-
utamide in normal and diabetic rats.
Methods
All animal experiments were performed in accordance
with our institutional animal ethics committee. Albino
rats of either sex (Mahaveer Enterprises, Hyderabad)
weighing between 125 – 175 g were used in the study.
They were housed five per cage at temperature 22 ± 2°C
and 12/12 h light/dark under controlled environment.
Rats were fed with standard pellet diet. (Mahaveer Enter-
prises, Hyderabad) and water ad libitum. They were
divided into 3 groups of five each. They were fasted for 18
h prior to the experiment allowing access to water only,
and the water was withdrawn during the experiment.
Blood samples were collected from the retro-orbital
plexus of each rat at 0, 0.5, 1, 1.5, 2, 4, 6 hr after drug
administration. Blood glucose levels were determined by
using GOD – POD method [7].
Group I received L-ascorbic acid 60 mg / kg body weight,
Group II received tolbutamide 20 mg/kg body weight and
Group III was given L-ascorbic acid (60 mg / kg body
weight) prior to the administration of tolbutamide 20
mg/kg body weight in normal rats. In clinical practice
tolbutamide and vitamin C are administered orally hence
in our study also this was administered orally.
Induction of diabetes
Albino rats of either sex weighing between 125 to 175 g
were fasted overnight before injection with alloxan.
Alloxan monohydrate was dissolved in saline solution
and was administered at a dose of 100 mg/kg body weight
intraperitonially. Animals were treated with 10% dextrose
Table 1: Percent blood glucose reduction (Mean ± SEM) with L-ascorbic acid/ tolbutamide / L-ascorbic acid + tolbutamide in normal 
rats (n= 5)
Time in hours L-ascorbic acid 60 mg/kg 
bd.wt.
Tolbutamide 20 mg/kg bd.wt. L-ascorbic acid 60 mg/kg 
bd.wt. + Tolbutamide 20 mg/
kg bd.wt.
0---
0.5 50.91 ± 0.49 10.08 ± 1.08 53.57 ± 2.01***
1 20.26 ± 3.14 15.56 ± 1.48 28.70 ± 1.75***
1.5 6.06 ± 1.3 18.75 ± 2.1 23.25 ± 1.72
2 1.65 ± 0.93 22.22 ± 2.13 29.78 ± 2.57
4 -2.83 ± 0.4 33.0 ± 0.69 45.21 ± 2.79**
6 - 10.28 ± 1.02 12.54 ± 2.5
Significance *** P < 0.001, **P < 0.01
Table 2: Percent blood glucose reduction (Mean ± SEM) with L-ascorbic acid/ tolbutamide / L-ascorbic acid + tolbutamide in diabetic 
rats (n = 5)
Time in hours L-ascorbic acid 40 mg/kg 
bd.wt.
Tolbutamide 20 mg/kg bd.wt. L-ascorbic acid 40 mg/kg 
bd.wt. + Tolbutamide 20 mg/
kg bd.wt.
0---
0.5 18.23 ± 1.88 3.03 ± 0.8 23.55 ± 2.37***
1 35.45 ± 3.26 7.83 ± 1.84 35.59 ± 4.48***
1.5 42.53 ± 1.78 18.58 ± 2.49 57.49 ± 1.63**
2 34.04 ± 2.22 37.97 ± 6.40 59.74 ± 1.22*
4 20.02 ± 3.32 45.09 ± 4.95 62.55 ± 0.64**
6 - 21.6 ± 1.94 39.43 ± 2.15***
Significance *** P < 0.001, **P < 0.01, *P < 0.05BMC Endocrine Disorders 2005, 5:2 http://www.biomedcentral.com/1472-6823/5/2
Page 3 of 4
(page number not for citation purposes)
orally to combat the early phase of hypoglycaemia. Rats
showing fasting blood glucose levels above 150 mg/dl
were selected for the study. They were divided into 3
groups of five each. Group I received L-ascorbic acid 40
mg/kg body weight and Group II received tolbutamide 20
mg/kg body weight while Group III was given L-ascorbic
acid 40 mg/kg prior to tolbutamide administration (20
mg/kg). L-ascorbic acid dose was fixed based on its
response, which produced above 40%.
Statistical analysis
The significance of blood glucose reduction produced by
L-ascorbic acid with tolbutamide compared to tolbuta-
mide control was determined by applying students
unpaired t-test and the significance is indicated by * mark.
Results
The presence of L-ascorbic acid upto 20 µg did not inter-
fere with the blood glucose estimation when tested with
different quantities in in vitro studies. In normal rats L-
ascorbic acid at the dose of 60 mg/kg body weight admin-
istered orally produced 50.91% blood glucose reduction
at 0.5 h and 20 mg/kg body weight of tolbutamide pro-
duced 33% at 4 h as peak effects. In the presence of L-
ascorbic acid (60 mg/kg), the action of tolbutamide was
early in onset and maintained for 6 h. In diabetic rats, oral
administration of L-ascorbic acid alone at the dose of 40
mg/kg body weight produced 42.53% blood glucose
reduction at 1.5 h and tolbutamide 20 mg/kg body weight
produced 45.09 at 4 h. Administration of L-ascorbic acid
40 mg/kg body weight prior to tolbutamide produced
antidiabetic activity at 0.5 h and was maintained for 6 h.
The percent blood glucose reduction with L-ascorbic acid
/ tolbutamide/ L-ascorbic acid + tolbutamide in normal
rats and diabetic rats were given in table 1 &2.
Discussion
The drug interaction studies are usually conducted in ani-
mal models to find out the mechanism before they are
conducted in humans. We have selected rat as animal
model since it is one of the animal, which synthesize
ascorbic acid and can be maintained easily in the labora-
tory conditions.
Reactive oxygen species (ROS) are thought to be impli-
cated in the pathogenesis of diabetes as well as other dis-
eases[8]. Reactive oxygen species usually comprise
radicals that have the ability to oxidize and damage DNA,
proteins and carbohydrates. Hyperglycaemia appears to
induce oxidative stress on cells and this can cause an
increase in the production of free radicals[9]. Human
antioxidant enzymes are mobilized during hyperglycae-
Percent Blood Glucose Reduction with L-ascorbic acid / tolb- utamide / L-ascorbic acid + tolbutamide in normal rats (n =  5) Figure 1
Percent Blood Glucose Reduction with L-ascorbic acid / tolb-
utamide / L-ascorbic acid + tolbutamide in normal rats (n = 
5)
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Percent Blood Glucose Reduction with L-ascorbic acid / tolb-
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mia, but they cannot meet the continued demand due to
increased oxidative stress[10]. This problem is either due
to decreased intake of needed precursors or an inability to
synthesise the antioxidant enzymes[11]. Antioxidant sup-
plementation may provide the only means to reverse this
process[12]. Use of typical antioxidants alone or in com-
bination may retard or even prevent the normal progres-
sion of diabetic complications.
It was reported that L-ascorbic acid levels were decreased
in diabetic patients and rats[13]. So it is felt that L-ascor-
bic acid supplementation may help in the treatment of
diabetes mellitus. In the present study L-ascorbic acid and
tolbutamide reduced blood glucose levels in normal &
diabetic rats in a dose dependent manner. L-ascorbic acid
when administered alone produced an early onset of
action 0.5 & 1.5 h in normal and diabetic rats respectively.
This early onset may be due to increase in the insulin
secretion which support earlier reports that L-ascorbic
acid supplementation increase the plasma insulin concen-
tration[14]. Tolbutamide when administered in therapeu-
tic dose produced the maximum effect at 4 h and was
maintained up to 6 h in both normal and diabetic rats. In
the presence of L-ascorbic acid the onset of action of tolb-
utamide was early and maintained for longer duration
compared to tolbutamide control. Tolbutamide acts by
stimulating insulin secretion (pancreatic)[15] and also by
increasing tissue uptake of glucose (extra pancreatic)[16].
The early onset of action was noticed to be due to L-ascor-
bic acid, which was maintained later due to tolbutamide
activity since both are reported to have influence on insu-
lin secretion [14,15].
Conclusion
The study indicates that additive action of L-ascorbic acid
on pharmacodynamic response of tolbutamide may be
useful to improve the tolbutamide activity in insulin
resistant cases and to postpone the occurrence of diabetic
complications. However further work on human patients
is required to confirm the observation in diabetic condi-
tion and usefulness of L-ascorbic acid as supplemental
agent for improved control of blood glucose levels when
administered along with sulfonylureas.
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